Celgene (CELG), LYSA Announce Initial REVLIMID Phase 3 Data in DLBCL; Primary Endpoint was Achieved
Tweet Send to a Friend
Celgene Corporation (NASDAQ: CELG) and the Lymphoma Study Association (LYSA) announced that the Lymphoma Academic Research Organisation (LYSARC) reported initial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
